bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE - Get Free Report) in a research report issued on Tuesday. The brokerage set a "sell" rating on the biotechnology company's stock.

Several other brokerages also recently weighed in on BLUE. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of bluebird bio in a report on Monday, September 16th. Robert W. Baird dropped their price target on shares of bluebird bio from $7.00 to $6.00 and set an "outperform" rating on the stock in a research note on Thursday, August 15th. Wells Fargo & Company reduced their price objective on shares of bluebird bio from $3.00 to $2.00 and set an "equal weight" rating for the company in a research report on Wednesday, September 25th. JPMorgan Chase & Co. cut bluebird bio from a "neutral" rating to an "underweight" rating in a research report on Friday, November 15th. Finally, Bank of America cut bluebird bio from a "buy" rating to a "neutral" rating and reduced their price target for the company from $3.00 to $0.50 in a report on Friday, November 15th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $3.03.

bluebird bio Stock Up 0.4 %

Shares of bluebird bio stock traded up $0.00 during trading hours on Tuesday, hitting $0.36. The company had a trading volume of 2,939,112 shares, compared to its average volume of 7,387,922. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. bluebird bio has a twelve month low of $0.29 and a twelve month high of $5.53. The company has a market cap of $70.60 million, a P/E ratio of -0.19 and a beta of 0.76. The company's 50-day moving average is $0.46 and its two-hundred day moving average is $0.76.

bluebird bio (NASDAQ:BLUE - Get Free Report) last released its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. The firm had revenue of $18.57 million for the quarter. Analysts anticipate that bluebird bio will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On bluebird bio

A number of large investors have recently added to or reduced their stakes in the business. Allegheny Financial Group LTD purchased a new position in bluebird bio during the second quarter worth $25,000. Bayesian Capital Management LP purchased a new stake in bluebird bio during the 1st quarter worth about $52,000. Price T Rowe Associates Inc. MD lifted its holdings in bluebird bio by 113.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 29,113 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of bluebird bio by 458.8% during the 1st quarter. SG Americas Securities LLC now owns 80,032 shares of the biotechnology company's stock worth $102,000 after purchasing an additional 65,710 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new stake in shares of bluebird bio during the third quarter worth about $42,000. 87.43% of the stock is owned by institutional investors and hedge funds.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.